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All Patients Low Risk High Risk
n427 p-valuen967 n540
Median LOS (25th,
75th percentile)
3 (2,4) 2 (2,4) 3 (2,6) 0.001
% readmitted within
1 year
2.1% (20) 2.2% (12) 1.9% (8) 0.71
Median # days to
readmission (25th,
75th percentile)
70.5 (28.5,
133.5)
107 (14,
137.5)
55 (35,
84.5)
0.82
In-hospital mortality 5.3% 0 12.0% 0.001
30-day mortality 5.8% 0.2% 12.9% 0.001
1-year 9.4% 3.9% 16.4% 0.001
n598 n306 n292
Any Complication 11.7% 6.5% 17.1% 0.001
CHF 1.2% 0.3% 2.1% 0.063*
Cardiogenic Shock 2.7% 0.3% 5.1% 0.001*
RBC Transfusion 6.5% 2.3% 11.0% 0.001*
New Dialysis 0.8% 0% 1.7% 0.027*
Total hospital costs,
mean(SD)
20,247 
31,265
16,968 
17545
23,683 
40,737
0.009
*Fisher’s exact test used to assess statistical significance
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Background: It is known that apolipoprotein B/apolipoprotein A-I ratio (ApoB/A-I
ratio) could be a risk factor for CAD. Moreover, there are growing evidences that
ApoB/A-I can serve as an indicator of coronary plaque regression. However, there is lack
of studies that showed causal relationship between plaque regression and clinical
outcomes. The aim of this study was to assess the influence of the reduction of ApoB/A-I
ratio, the surrogate of plaque regression, on the outcomes after percutaneous coronary
intervention (PCI) in patients acute myocardial infarction (AMI).
Methods: Between November 2005 to September 2007, we measured serum Lp(a),
ApoB and ApoA-I level on admission and six-month follow-up in 1,014 consecutive AMI
patients (63.712.4 years, 723 men). We divided patients into two groups according to
ApoB/A-I ratio reduction (PR Group [plaque regression group]: ApoB/A-I ratio on
admission  six-month follow-up, non-PR Group [non-plaque regression group]:
ApoB/A-I ratio on admission  six-month follow-up).
Results: There were more men in PR Group (78.0% vs. 65.2%, p0.188) but, no
significant differences in age between groups. Particularly, non-PR group showed better
left ventricular ejection fraction than PR group (56.211.1 vs. 57.314.3 %, p0.003).
There was a trend toward more TIMI 0 flows in PR Group (66.1% vs. 55.5%, p0.057),
while more TIMI 3 flows were observed (26.3% vs. 40.3%, p0.018) in non-PR Group.
CK (1541.01680.0 vs. 1770.02529.1 U/L, p0.003) and CK-MB level (93.5104.6
vs. 104.4131.5 U/L, p0.010) were higher in non-PR Group than PR Group.
Lipoprotein (a) level was also higher in non-PR group (30.725.6 vs. 31.636.1 mg/dl,
p0.018). In analysis of clinical outcomes, one-year major cardiac adverse events
(MACE) was higher in non-PR group (17.1 vs. 21.6 %, p0.032). In Kaplan-Meier
analysis, PR group showed more favorable MACE-free survival rate than that of non-PR
group (p0.001 by Log-Rank test).
Conclusions: The reduction of ApoB/A-I ratio during follow-up may predict favorable
long-term outcome after PCI in patients with AMI. This may suggest that coronary plaque
regression by intensive statin therapy can also be beneficial to clinical outcomes after PCI
in these patients.
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Background: Guidelines discourage multi-vessel angioplasty at the time of ST elevation
myocardial infarction. This was apparently confirmed by a meta-analysis of predomi-
nantly registry data (Vlaar et al. J Am Coll Cardiol. 2011; 58(7):692-703). However, the
results of this analysis may have been exposed to the inherent allocation bias within
registries; if registry clinicians preferentially allocated STEMI patients with a higher risk
of mortality to multi-vessel angioplasty, the mortality of this therapy would appear
unfairly increased leading to misleading conclusions.
Methods: The 10 studies in the Vlaar analysis comparing culprit only to multi-vessel
PPCI (35008 patients, 96% of the ‘non-network’ analysis by Vlaar et al, 4 registries
excluded due to insufficient data) were re-analysed to determine if higher risk patients
were more likely to be allocated to multi-vessel PPCI. A weighted random effects
meta-regression was performed to determine if biased allocation of high risk patients
could explain the difference in mortality between the two therapies (STATA Corp, Texas,
USA).
Results: We demonstrate that higher risk patients are more likely to be allocated to
multi-vessel PPCI (pooled OR 0.80, 95% CI 0.69-0.92); furthermore when we adjust for
this difference in higher risk patient allocation across the studies there is no mortality
difference between culprit only and multi-vessel angioplasty at the time of STEMI
(adjusted OR 0.86, 95% CI 0.51-1.46).
Conclusions: Our findings highlight the limitations of using registry data for comparative
efficacy research and suggest multi-vessel angioplasty at the time of STEMI should not be
discouraged on the basis of current data. An adequately powered randomised controlled
trial (RCT) should be performed to answer this question.
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Louis Kohl1, Ross Garberich1, Hannah Yang1, David Hildebrandt1,
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1Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital,
Minneapolis, MN
Background: ST-elevation myocardial infarction (STEMI) patients with prior coronary
artery bypass graft (CABG) have been reported to have worse outcomes but the majority
of data comes from the thrombolytic era.
Methods: A comprehensive prospective regional STEMI program database was queried
from 4/03 to 12/11. We sought to determine contemporary outcomes of STEMI patients
with prior CABG in a large, prospective, regional STEMI system.
Results: Of 3552 consecutive STEMI patients, 250 (7.1%) had prior CABG. In these 250
patients, the culprit vessel was the SVG in 81 (32%), a native vessel in 99 (40%) and there
was no clear culprit in 57 (23%). No patients had a LIMA as a culprit. Patients with prior
CABG were older, more likely to be male and have diabetes and less likely to be current
smokers. The prior CABG patients had lower EF and were less likely to have an
intervention. In the prior CABG patients, a SVG culprit was more likely to present with
cardiogenic shock and there was a trend toward less intervention (p0.08) and increased
in-hospital and 30 day mortality (p  0.08) in the SVG-culprit group which narrowed at
one year. In patients with a SVG culprit, absence of intervention conferred a greater risk
of mortality up to one year (40% vs. 8.5%, p0.005).
Conclusions: In a large, prospective regional STEMI system with a PCI based
reperfusion strategy, patients with prior CABG and a SVG culprit have similar outcomes
despite being having prior CABG. Prior data have suggested worse outcomes in this
group, but this may have reflected lower rates of PCI in patients with SVG culprit.
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Prior CABG
(n250)
No Prior
CABG
(n3292) P-Value
Culprit SVG
(n81)
Native
Culprit
(n99)
No Culprit
(n57) P-Value
Age (Yrs),
mean(SD)
69.4 	/
12.0
62.0 	/
14.3
0.001 68.5 	/
11.4
68.7
	/
11.6
69.2 	/
12.4
0.90/
0.95
Male, (%) 204 (81.6) 2324
(70.6)
0.001 67 (82.7) 83
(83.8)
45 (79.0) 0.84/
0.74
BMI, mean(SD) 28.6 	/
5.7
28.9 	/
6.0
0.40 28.6 	/
4.7
28.5
	/
6.0
28.8 	/
6.7
0.90/
0.97
OOHCA, (%) 15 (6.0) 296 (9.0) 0.11 3 (3.7) 6 (6.1) 4 (7.0) 0.47/
0.67
Shock Pre-PCI,
(%)
20 (8.0) 279 (8.5) 0.79 11 (13.6) 4 (4.0) 4 (7.0) 0.021/
0.061
History of
smoking, (%)
147 (59.5) 1995
(61.0)
0.64 52 (64.2) 47
(48.0)
42 (73.7) 0.03/
0.004
Current Smoker-,
(%)
47 (32.0) 1233
(61.8)
0.001 17 (32.7) 18
(38.3)
10 (23.8) 0.56/
0.34
Diabetes, (%) 89 (35.7) 518 (15.8) 0.001 29 (35.8) 30
(30.6)
23 (40.4) 0.46/
0.46
EF (%), mean(SD) 45.3 	/
14.4
47.4 	/
13.3
0.020 45.0 	/
13.8
45.4
	/
14.6
48.2 	/
14.3
0.82/
0.42
Killip Class 0.98 0.061/
0.15
0/1, (%) 218 (87.2) 2867
(87.1)
67 (82.7) 91
(91.9)
48 (84.2)
2/4, (%) 32 (12.8) 423 (12.9) 14 (17.3) 8 (8.1) 9 (15.8)
Intervention
Done, (%)
169 (67.6) 2622
(79.8)
0.001 71 (87.7) 94
(95.0)
2 (3.5) 0.078/
0.001
D2B (mins),
median (25th,
75th percentile)
98 (74,
124)
95 (74,
124)
0.35 95 (75,
119)
98
(75,
119)
107 (84,
130.5)
0.87**/
0.27**
Death In Hospital,
(%)
12 (4.8) 165 (5.0) 0.88 6 (7.4) 2 (2.0) 2 (3.5) 0.081/
0.19
Death at 30
Days, (%)
12 (4.8) 189 (5.7) 0.54 6 (7.4) 2 (2.0) 2 (3.5) 0.081/
0.19
Death at 1 Year,
(%)
27 (10.8) 295 (9.0) 0.33 10 (12.4) 7 (7.1) 4 (7.0) 0.23/0.40
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Background: Several clinical and angiographic scores have been proposed for the
prediction of the outcome of patients with myocardial infarction undergoing primary
percutaneous coronary angiography (PCI). The aim of this study was to assess the ability
of Clinical Syntax Score (CSS) for predicting outcome late after successful primary PCI.
Methods: 345 consecutive patients that underwent successful primary PCI due to STEMI
in our hospital were recruited out of 361 primary PCIs. CSS was calculated for each
patient as previously described. The patients were followed by outpatient visit or
telephone for 2 years. Endpoints included all-cause death, cardiac death, repeat revascu-
larization (RR), stent thrombosis (ST) and major adverse cardiac event (MACE), defined
as the composite of death, myocardial infarction, or target vessel revascularization.
Results: The median follow-up period was 476 days (mean 4965 days). Table 1
presents the 2-year outcomes according to CSS tertile, while the figure shows Kaplan-
Meier curves for freedom from cardiac death and MACE, respectively, stratified by CSS
tertile. CSS score was higher in patients with death or cardiovascular death, RR and
MACE.
CSS LOW
(n117)
CSS MID
(n109)
CSS HIGH
(n119) p-value
Total Death 6 (5.1%) 14 (12.8%) 22 (18.4%) 0.007
Cardiac death 1(0.8%) 5 (4.5%) 13 (10.9%) 0.02
ST 0 (0%) 0 (0%) 2(1.6%) 0.14
RR 5 (4.2%) 4(3.6%) 15 (12.6%) 0.01
MACE 5 (4.2%) 6 (5.5%) 20(16.8%) 0.001
Conclusions: CSS is a reliable tool for assessing outcome after successful PCI in patients
with myocardial infarction and successful primary PCI.
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Background: There were no published data regarding the clinical efficacy and safety of
second generation drug-eluting stent (zotarolimus-eluting stent with biolinx polymer,
ZES-BP, Endeavor resolute) following primary percutaneous coronary intervention (PCI)
in ST-elevation myocardial infarction (STEMI). We evaluated the one-year outcome of
zotarolimus-eluting stent with biolinx polymer versus to 1st generation (sirolimus-eluting
stent, SES and paclitaxel-eluting stent, PES) and 2nd generation (zotarolimus-eluting
stent, ZES and everolimus-eluting stent, EES) drug-eluting stents(DES) for the treatment
of STEMI.
Methods: A prospective, open-labeled, multi-center cohort has been performed. The
primary endpoint was major adverse cardiac event (MACE): the composite of cardiac
death (CD), recurrent MI and ischemia-driven target vessel revascularization (TVR) at 1
year. Stent thromboses (ST) by ARC definition were analyzed.
Results: Total 975 patients (ZES-BP178, EES197, ZES203, SES203,
PES194) were analyzed. One-year MACE were 3.4%, 2.0%, 5.9%, 3.4% and 5.7% in
ZES-BP, EES, ZES, SES and PES group, respectively (pns). Cardiac death were 2.3%,
1.0%, 2.5%, 1.5% and 1.0% in ZES-BP, EES, ZES, SES and PES group, respectively
(pns).
Conclusions: Compared to 1st and 2nd generation DES (SES and PES, ZES), EES and
ZES-BP showed similar one-year clinical outcomes in terms of MACE in patients with
STEMI following primary PCI and no stent thrombosis.
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Ross Garberich1, Stephanie Rutten-Ramos1, Anil Poulose1, David Larson1,
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Background: Recent studies suggest door in-door out (DIDO) time may predict
outcomes in ST-elevation myocardial infarction (STEMI) patients transferred from a
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